Recombinant Mouse CD39L1 (C-6His)

Recombinant Mouse CD39L1 (C-6His)

Size1:10μg price1:$168
Size2:50μg price2:$465
Size3:500μg price3:$2350
SKU: PHM0553 Category: Target Proteins Tags: ,

Datasheet

Name

Recombinant Mouse CD39L1 (C-6His)

Purity

Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level

<1 EU/µg as determined by LAL test.

Construction

Recombinant Mouse Ecto-Nucleoside Triphosphate Diphosphohydrolase 2 is produced by our Mammalian expression system and the target gene encoding Cys26-Ser462 is expressed with a 6His tag at the C-terminus.

Accession #

O55026

Host

Human Cells

Species

Mouse

Predicted Molecular Mass

49.2 KDa

Buffer

Supplied as a 0.2 μm filtered solution of 50mM Tris-HCl, 10mM CaCl2, 150mM NaCl, 10% Glycerol, pH 7.5.

Form

Liquid

Shipping

The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

 

 

 

Alternative Names

Ectonucleoside triphosphate diphosphohydrolase 2; Entpd2

 

Background

CD39L1 protein (ENTPD2 or NTPDase2) is a member of the ecto-nucleoside triphosphate diphosphohydrolase family which the main role is termination of purinergic signaling. CD39L1 gene encodes a precursor protein with 495 amino acid residues which generates a 437 amino acid residues mature protein after processing. It is an ecto-nucleotidase that found on the surface of vascular adventitial cells and accessory vascular cells. CD39L1 is a Ca2+- and Mg2+-dependent enzyme that activates platelets by preferentially converting ATP to ADP. CD39L1 plays a role in regulating thrombosis and inflammation which is considered to be a therapeutic target for thromboregulation and the treatment of vascular inflammation. Alternative splicing of CD39L1 gene results in multiple transcript variants.

 

Note

For Research Use Only , Not for Diagnostic Use.